The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Ipsen SA stock forecast from 0 analysts, the average analyst target price for Ipsen SA is not available over the next 12 months. Ipsen SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Ipsen SA is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Ipsen SA’s stock price was EUR 108.00. Ipsen SA’s stock price has changed by -1.55% over the past week, +4.45% over the past month and -9.24% over the last year.
No recent analyst target price found for Ipsen SA
No recent average analyst rating found for Ipsen SA
Company Overview Ipsen SA
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France. Address: 65, quai Georges Gorse, Boulogne-Billancourt, France, 92100 Read Less
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metas...Read More
Frequently Asked Questions About Ipsen SA (IPN:PA) Stock
Stock Target Advisor's fundamental analysis for Ipsen SA's stock is Slightly Bullish .
IPN:PA stock's dividend yield is 1.11%.
Our analysis grades IPN:PA stock's dividend yield at F. This means that IPN:PA stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the PA exchange.
Based on this IPN:PA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on IPN:PA's stock to indicate what its average analyst target is.
IPN:PA stock's Price/Earning ratio is 13.60.
Our analysis grades IPN:PA stock's Price / Earning ratio at F. This means that IPN:PA stock's Price/Earning ratio is above 50% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the PA exchange.
Based on this IPN:PA may be fairly valued for its sector
The last closing price of IPN:PA's stock was EUR 108.00.
The most recent market capitalization for IPN:PA is EUR 8.93B.
Unfortunately we do not have enough analyst data on IPN:PA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Ipsen SA's stock.
As per our most recent records Ipsen SA has 5,325 Employees.
Ipsen SA's registered address is 65 Quai Georges Gorse, Boulogne-Billancourt, France, 92100.
You can get more information about it from Ipsen SA's website at https://www.ipsen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Ipsen SA (IPN:PA) Stock
Stock Target Advisor's fundamental analysis for Ipsen SA's stock is Slightly Bullish .
IPN:PA stock's dividend yield is 1.11%.
Our analysis grades IPN:PA stock's dividend yield at F. This means that IPN:PA stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the PA exchange.
Based on this IPN:PA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on IPN:PA's stock to indicate what its average analyst target is.
IPN:PA stock's Price/Earning ratio is 13.60.
Our analysis grades IPN:PA stock's Price / Earning ratio at F. This means that IPN:PA stock's Price/Earning ratio is above 50% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the PA exchange.
Based on this IPN:PA may be fairly valued for its sector
The last closing price of IPN:PA's stock was EUR 108.00.
The most recent market capitalization for IPN:PA is EUR 8.93B.
Unfortunately we do not have enough analyst data on IPN:PA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Ipsen SA's stock.
As per our most recent records Ipsen SA has 5,325 Employees.
Ipsen SA's registered address is 65 Quai Georges Gorse, Boulogne-Billancourt, France, 92100.
You can get more information about it from Ipsen SA's website at https://www.ipsen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IPN:PA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
